Page 62 - Genentech News Today

Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to...

DUBLIN--(BUSINESS WIRE)--The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.CD3 protein has emerged as a promising target that has significant therapeutic potential in various diseases. Over the years, several CD3 antibod...

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study will evaluate the effect of ACI-35.030...

But editorialists note that with recent advances, 'it is hard to justify' use of combination

In this article, we discuss the 16 biggest positions in the ARK Invest portfolio.

Adding atezolizumab to treatment with carboplatin improved survival outcomes in patients with metastatic TNBC in a phase 2 trial. Adding atezolizumab to treatment with carboplatin improved survival outcomes in patients with metastatic TNBC in a phase 2 trial.

Applying the Supreme Court’s Amgen v. Sanofi decision for the first time, the Federal Circuit recently affirmed a district court decision finding claims to antibodies characterized by...

On November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. (“Plaintiffs”) filed a BPCIA complaint (“Complaint”) against Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s...

'In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma.'

According to Aristotle, you can develop a great speech by using 3 steps: Ethos, Logos, and Pathos. Entrepreneurs can also use his 3 steps to develop a great pitch deck.